IC
DMRA

Ikarian Capital’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Ikarian Capital’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.69M Buy
335,710
+50,000
+18% +$1.29M 0.71% 39
2025
Q4 		$6.57M Buy
+285,710
New +$4.97M 0.51% 54

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Ikarian Capital's DMRA Position: Q1 2026 in Review

Ikarian Capital increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 18% in Q1 2026, buying an estimated $1.29M and bringing the position to 335,710 shares worth $8.69M. The position accounts for 0.71% of the portfolio, ranked #39.

Ikarian Capital first reported a position in DMRA in Q4 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Ikarian Capital held 335,710 shares of Damora Therapeutics, Inc. Ordinary Shares worth $8.69M as of Q1 2026.
  • Ikarian Capital bought 50,000 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $1.29M.
  • Damora Therapeutics, Inc. Ordinary Shares made up 0.71% of Ikarian Capital's portfolio in Q1 2026, its #39 holding.
  • Ikarian Capital first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.